Cargando…

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes

PURPOSE: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic macular edema (CI-DME). METHODS: Fifty-seven...

Descripción completa

Detalles Bibliográficos
Autores principales: Moradian, Siamak, Soheilian, Masoud, Asadi, Mahsan, Baghi, Abdolreza, Safi, Hamid, Abtahi, Seyed-Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PUBLISHED BY KNOWLEDGE E 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172803/
https://www.ncbi.nlm.nih.gov/pubmed/37181609
http://dx.doi.org/10.18502/jovr.v18i2.13182
_version_ 1785039692780011520
author Moradian, Siamak
Soheilian, Masoud
Asadi, Mahsan
Baghi, Abdolreza
Safi, Hamid
Abtahi, Seyed-Hossein
author_facet Moradian, Siamak
Soheilian, Masoud
Asadi, Mahsan
Baghi, Abdolreza
Safi, Hamid
Abtahi, Seyed-Hossein
author_sort Moradian, Siamak
collection PubMed
description PURPOSE: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic macular edema (CI-DME). METHODS: Fifty-seven eyes of 36 patients with CI-DME were included in this prospective interventional case series. Structural optical coherence tomography (OCT) and enhanced depth imaging OCT were performed at baseline followed by three monthly 1.25 mg IVZ injections. Changes of SCT, CMT, and BCVA at each follow-up session were assessed. The association between baseline SCT and its monthly changes with final visual and anatomical outcomes were also assessed. RESULTS: CMT at baseline, and at the first, second, and third month follow-up sessions were 396 [Formula: see text] 119, 344 [Formula: see text] 115, 305 [Formula: see text] 89, and 296 [Formula: see text] 101 μm, respectively (P-value [Formula: see text] 0.001). SCT at baseline, and at months one, two, and three were 236 [Formula: see text] 47, 245 [Formula: see text] 56, 254 [Formula: see text] 54, and 241 [Formula: see text] 54 μm, respectively (P-value [Formula: see text] 0.99). Corresponding figures for BCVA were 0.58 [Formula: see text] 0.29, 0.47 [Formula: see text] 0.31, 0.4 [Formula: see text] 0.24, and 0.37 [Formula: see text] 0.23 LogMAR, respectively (P-value [Formula: see text] 0.001). There was a statistically significant positive correlation between BCVA and CMT changes following IVZ injections (P-value [Formula: see text] 0.001). However, there were no significant correlations between SCT changes and visual acuity (VA) and CMT changes following IVZ injections. CONCLUSION: IVZ improved visual outcomes and macular thickness profiles in patients with CI-DME. However, IVZ had no significant effect on SCT. Baseline SCT and its monthly changes had no association with visual and anatomical outcomes.
format Online
Article
Text
id pubmed-10172803
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher PUBLISHED BY KNOWLEDGE E
record_format MEDLINE/PubMed
spelling pubmed-101728032023-05-12 Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes Moradian, Siamak Soheilian, Masoud Asadi, Mahsan Baghi, Abdolreza Safi, Hamid Abtahi, Seyed-Hossein J Ophthalmic Vis Res Original Article PURPOSE: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic macular edema (CI-DME). METHODS: Fifty-seven eyes of 36 patients with CI-DME were included in this prospective interventional case series. Structural optical coherence tomography (OCT) and enhanced depth imaging OCT were performed at baseline followed by three monthly 1.25 mg IVZ injections. Changes of SCT, CMT, and BCVA at each follow-up session were assessed. The association between baseline SCT and its monthly changes with final visual and anatomical outcomes were also assessed. RESULTS: CMT at baseline, and at the first, second, and third month follow-up sessions were 396 [Formula: see text] 119, 344 [Formula: see text] 115, 305 [Formula: see text] 89, and 296 [Formula: see text] 101 μm, respectively (P-value [Formula: see text] 0.001). SCT at baseline, and at months one, two, and three were 236 [Formula: see text] 47, 245 [Formula: see text] 56, 254 [Formula: see text] 54, and 241 [Formula: see text] 54 μm, respectively (P-value [Formula: see text] 0.99). Corresponding figures for BCVA were 0.58 [Formula: see text] 0.29, 0.47 [Formula: see text] 0.31, 0.4 [Formula: see text] 0.24, and 0.37 [Formula: see text] 0.23 LogMAR, respectively (P-value [Formula: see text] 0.001). There was a statistically significant positive correlation between BCVA and CMT changes following IVZ injections (P-value [Formula: see text] 0.001). However, there were no significant correlations between SCT changes and visual acuity (VA) and CMT changes following IVZ injections. CONCLUSION: IVZ improved visual outcomes and macular thickness profiles in patients with CI-DME. However, IVZ had no significant effect on SCT. Baseline SCT and its monthly changes had no association with visual and anatomical outcomes. PUBLISHED BY KNOWLEDGE E 2023-04-19 /pmc/articles/PMC10172803/ /pubmed/37181609 http://dx.doi.org/10.18502/jovr.v18i2.13182 Text en Copyright © 2023 Moradian et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Moradian, Siamak
Soheilian, Masoud
Asadi, Mahsan
Baghi, Abdolreza
Safi, Hamid
Abtahi, Seyed-Hossein
Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
title Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
title_full Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
title_fullStr Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
title_full_unstemmed Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
title_short Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
title_sort ziv-aflibercept in diabetic macular edema: relation of subfoveal choroidal thickness with visual and anatomical outcomes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172803/
https://www.ncbi.nlm.nih.gov/pubmed/37181609
http://dx.doi.org/10.18502/jovr.v18i2.13182
work_keys_str_mv AT moradiansiamak zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes
AT soheilianmasoud zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes
AT asadimahsan zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes
AT baghiabdolreza zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes
AT safihamid zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes
AT abtahiseyedhossein zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes